Article Text

Download PDFPDF

722 Real-world patterns of care and outcomes in patients with microsatellite-instability high tumors in advanced endometrial cancer in the United States
  1. S Kelkar1,
  2. S Corman1,
  3. C Macahilig2,
  4. V Prabhu3,
  5. N Rusibamayila1,
  6. S Odak2,
  7. R Orlowski3 and
  8. L Duska4
  1. 1OPEN Health, Evidence and Access, Bethesda, MD, USA
  2. 2RTI-Health Solutions, Surveys and Observational Studies, Research Triangle, NC , USA
  3. 3Merck and Co., Inc., Outcomes Research (Oncology-Cervical and Endometrial), Kenilworth, NJ, USA
  4. 4University of Virginia Health System, Gynecologic Oncology Division Department of Obstetrics and Gynecology, Charlottesville, VA, USA


Introduction/Background*New/emerging therapies based on microsatellite instability (MSI) prognostic biomarker are altering the treatment landscape for advanced endometrial cancer (aEC). The real-world outcomes in aEC patients with MSI-high/deficient mismatch repair (MSI-H/dMMR) tumor status is not well understood.

Methodology Endometrial Cancer Health Outcomes (ECHO) is a multicenter retrospective chart review study in women diagnosed with aEC in the US. Physicians extracted de-identified data from medical records of women (≥18 years-old) diagnosed with inoperable aEC, with known MSI/MMR status, who progressed after prior systemic therapy between 07/01/2016-07/30/2019. Data included patient demographics, clinical/treatment characteristics, and clinical outcomes. Kaplan-Meier analyses were performed to estimate time to treatment discontinuation, real-world progression-free survival (rwPFS) and overall survival (OS). The study was IRB approved.

Result(s)*Among 130 MSI-H/dMMR aEC patients who progressed on a prior systemic therapy, mean age was 62 years, 57% had endometrioid carcinoma histology, and 93% had ECOG 0-1. As 2nd-line therapy, 79% of patients received immunotherapy (IO) ± chemotherapy (CT) (pembrolizumab monotherapy=71%), 14% received CT only, and 7% received hormonal or other therapy (HT/OT). Median duration of 2nd line therapy was 14 months. Median rwPFS from initiation of 2nd-line therapy was 17 months (95% confidence interval [CI]: 13-n/a) [IO±CT: 29 months (95% CI: 18-n/a); CT: 4 months (95% CI: 2-9)]. Median OS from 2nd-line therapy initiation was 30 months (95% CI: 18-n/a) [IO±CT: median not reached (95% CI: 30-n/a); CT: 5.5 months (95% CI: 4-n/a)]. (Table 1)

Abstract 722 Table 1

Time to Treatment discontinuation, overall survival, and real-world progression free survival in MSI-High or dMMR aEC patients since initiation of 2nd line of therapy overall and stratified by treatment category

Conclusion*In real-world practice, most MSI-high/dMMR aEC patients in the US who failed a prior systemic therapy, initiated immunotherapy with favorable outcomes.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.